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Recent evidence has challenged the default assumption that all 
DNA-reactive alkylating agents exhibit a linear dose-response. 
Emerging evidence suggests that the model alkylating agents 
methyl- and ethylmethanesulfonate and methylnitrosourea (MNU) 
and ethylnitrosourea observe a nonlinear dose-response with a no 
observed genotoxic effect level (NOGEL). Follow-up mechanis-
tic studies are essential to understand the mechanism of cellular 
tolerance and biological relevance of such NOGELs. MNU is one 
of the most mutagenic simple alkylators. Therefore, understand-
ing the mechanism of mutation induction, following low-dose 
MNU treatment, sets precedence for weaker mutagenic alkylat-
ing agents. Here, we tested MNU at 10-fold lower concentra-
tions than a previous study and report a NOGEL of 0.0075 µg/ml 
(72.8nM) in human lymphoblastoid cells, quantified through the 
hypoxanthine (guanine) phosphoribosyltransferase assay (OECD 
476). Mechanistic studies reveal that the NOGEL is depend-
ent upon repair of O6-methylguanine (O6MeG) by the suicide 
enzyme O6MeG-DNA methyltransferase (MGMT). Inactivation 
of MGMT sensitizes cells to MNU-induced mutagenesis and shifts 
the NOGEL to the left on the dose axis.
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To reduce the potential risk of human cancer and heritable 
genetic defects, consumer products and environmental pol-
lutants are tested for their genotoxic potential. The default 
assumption is that all doses of direct-acting genotoxins cause 
appreciable genotoxicity and “no safe level” exists. However, 
recent in vitro and in vivo experimental evidence, using model 
alkylating agents, contradicts this assumption of linearity in the 
low-dose region (Doak et al, 2007). Low levels of two com-
monly used alkyl alkanesulfonates (methyl- and ethylmethane-
sulfonate; MMS and EMS) show clear no observed genotoxic 
effect levels (NOGELs) for gene mutation and chromosome 
damage in vitro and in vivo (Doak et  al., 2007; Gocke and 
Müller, 2009; Gollapudi et  al., 2013). Furthermore, recent 
nonlinear dose-responses with NOGELs have been observed 
for two potent mutagens, methylnitrosourea (MNU) and ethyl-
nitrosourea (Bryce et al., 2010; Dobo et al., 2011; Lynch et al., 
2011; Pottenger et al., 2009).
There is considerable impetus to define the underlying 
mechanism of cellular tolerance responsible for each NOGEL. 
A  number of cytoprotective mechanisms have been postu-
lated (Doak et al., 2007; Speit et al., 2000). It has been shown 
that adducts accumulate at nonmutagenic doses of MMS 
(Swenberg et al., 2008), thereby implicating the role of postad-
duct DNA repair mechanisms in protection against mutations 
at low doses. Subsequently, Zaïr et al. (2011) showed a role for 
N-methylpurine-DNA glycosylase (MPG, alias AAG) in the 
repair of EMS-induced adducts at the clastogenic NOGEL and 
below. However, MPG was not linked to the mutagenic NOGEL 
in the same study. It seems likely that the mechanism of cyto-
protection is mechanism of action specific. Such mechanistic 
studies are essential for determining the mutagenic and carcino-
genic potency of alkylating agents. This is of particular impor-
tance for MNU as it sets precedence for weaker mutagens.
The reaction of alkylating agents with DNA is well defined 
(Beranek, 1990). Consequences of alkylating agent exposure 
are exerted through premutagenic adducts. The mutagenic 
potential of simple alkylating agents depends upon the adducts’ 
half-life, efficiency of repair, and propensity to miscode during 
DNA replication (Jenkins et  al., 2005). The structure of O6-
methylguanine (O6MeG) resembles adenine and has significant 
miscoding potential during replication (Beranek et al., 1983). It 
is recognized that O6MeG is the most mutagenic methyl adduct 
(Beranek, 1990). MNU is highly electrophilic (low s value 
of 0.42) and methylates sites of low nucleophilicity, e.g., O6-
guanine. MNU produces O6MeG to a greater extent than agents 
(e.g., MMS) with s values approaching 1, which is likely to 
account for the difference in mutagenic potential between these 
agents (Doak et al., 2007).
The biological relevance of O6MeG in carcinogenicity, cyto-
toxicity, and mutagenicity was first noted by Loveless (1969), 
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who observed the predominance of GC → AT transitions fol-
lowing exposure of bacteriophages to MNU. Furthermore, 
O6MeG has been implicated in the MNU-induced transforma-
tion of ras proto-oncogenes (Jacoby et  al., 1992; Mariyama 
et  al., 1989; Newcomb et  al., 1995; Sukumar, 1989) and in 
cancer initiation (Becker et  al., 1996; Bos, 1989). O6MeG 
is efficiently repaired by O6MeG-DNA methyltransferase 
(MGMT) in a suicide reaction that inactivates MGMT (Kaina 
et al., 2007). The methyl adduct is irreversibly transferred to 
a cysteine residue in the active site of the protein. The reac-
tion is stoichiometric, where the number of adducts that can be 
repaired is equal to the number of active intracellular MGMT 
molecules. Consequently, the cell has limited capacity to repair 
O6MeG, and MGMT can be depleted (reviewed by Pegg and 
Byers (1992)). Depletion of MGMT leaves the cell sensitive to 
alkylation damage (Hirose et al., 2003), and the rate of MGMT 
regeneration maybe cell-type specific, depending upon basal 
expression kinetics. Regeneration occurred faster in mitogen 
stimulated T cells (Gerson, 1988), suggesting that cell division 
is important (Sklar et al., 1981). It is well established that in 
rats, MGMT has an expression induction system in response 
to alkylation- and x-ray–induced damage (Fritz et  al., 1991; 
Grombacher et al., 1996) possibly involving the transcription 
factors p53, AP-1, and SP1 (Grombacher et al., 1998; Harris 
et al., 1996; Rafferty et al., 1996). Very little evidence shows the 
same induction system in humans (Doak et al., 2008) despite 
upregulation by corticosteroids, phorbol-12-myristate-13-ace-
tate (TPA), and other protein kinase C activators in HeLa S3 
cells (Boldogh et al., 1998; Grombacher et al., 1996). Suffice to 
say, uncertainty exists about the transcriptional regulation and 
protein turnover of MGMT within human cells.
The aim of this study was to identify the biological mecha-
nism of mutagenesis by low-dose MNU exposure at the hypox-
anthine (guanine) phosphoribosyltransferase (H(G)PRT) locus 
in a human cell line. This is in order to substantiate the exist-
ence of NOGELs for point mutation induction by direct-acting 
alkylating agents.
MATERIALs AND METHODs
Reagents. MNU, HAT supplement (2 × 10−4M hypoxanthine, 8 × 10−7M 
aminopterin, and 3.5 × 10−5M thymidine), HT supplement (2 × 10−4M hypoxan-
thine and 3.5 × 10−5M thymidine), 6-thioguanine, and O6-benzylguanine were 
purchased from Sigma-Aldrich (Gillingham, UK). All powdered reagents were 
reconstituted according to manufacturer’s instructions. To prevent leaching of 
plastics under solvents, stocks were diluted in glass vials (Sigma). The exact 
purity of MNU is not known. Manufacturers state up to 87%. The concentra-
tions shown here are nominal, and this purity should be taken into account 
should this study be compared to one using MNU of 100% purity.
Cell culture. AHH-1 (TK+/−) cells were purchased from American Type 
Culture Collection (Middlesex, UK) and cultured under conditions specified by 
Doak et al. (2007).
Hypoxanthine phosphoribosyltransferase  assay. The hypoxanthine 
phosphoribosyltransferase (HPRT) assay was performed as detailed in the 
study by Doak et al. (2007) and following MGMT inactivation. Each replicate 
was treated with a new stock of MNU. Twenty-four-hour treatment with the 
dose range of MNU utilized here caused a maximum of 40 ± 5% (mean ± SD) 
toxicity as adjudged by plating efficiency (PE) (Fig.  1). This is within the 
acceptable range for testing, as dictated in the OECD guideline 486 (OECD, 
1997). A two-tailed t-test compared PE of each dose with PE of solvent control. 
It was noted that the mutant frequency (MF) of the solvent control (dimethyl 
sulfoxide [DMSO]) is indistinguishable from that of the untreated control, with 
MF being 1.4 × 10−5 ± 1.8 × 10−6 (mean ± SD) and 1.4 × 10−5 ± 3.2 × 10−6, respec-
tively. A one-way ANOVA revealed that they were not significantly different 
(p = 0.952) and were combined to increase statistical power.
Inactivation of MGMT. AHH-1 cells were treated with 10µM O6BG and 
incubated at 37ºC, 5% CO
2
 for 1 h before MNU treatment.
Cytotoxicity assessment using relative population doubling. Toxicity and 
cytostasis of MNU ± O6BG was determined by relative population doubling 
(RPD) as detailed by Zaïr et al. (2011).
Endpoint PCR amplification of HPRT cDNA. Total RNA was extracted 
using RNeasy kit (Qiagen, Sussex, UK), under manufacturer’s instructions, from 
enumerated single cell clones (Johnson, 2012). Residual genomic DNA was 
removed through DNase I digestion (Qiagen). The quality, purity, and quantity 
of RNA were assessed through spectrophotometry. Two micrograms of RNA 
was used for cDNA synthesis using oligo (dT) primers of the RETROscript 
cDNA synthesis kit (Applied Biosystems, Warrington, UK). HPRT cDNA was 
targeted using overlapping primers to reduce amplicon length and improve effi-
cacy of PCR. Primers were designed using Beacon designer software (Premier 
Biosoft). These were as follows: forward, 5′-GAACCTCTCGGCTTTCCC-3′ 
and reverse, 5′-TGCCAGTGTCAATTATATCTTCC-3′, which targeted 52 to 
588 bp of the HPRT sequence and a second pair to amplify from position 524 to 
1238 bp. These were forward 5′-GATGATCTCTCAACTTTAACTGG-3′ and 
reverse 5′-CTTACTTTTCTAACACACGGTGG-3′. Separate reactions were 
established for each primer pair according to instructions supplied with GoTaq 
flexi DNA polymerase (Promega, Southampton, UK) supplemented with 
0.2µM primer, 1.5 U GoTaq polymerase, and 2 µl completed cDNA reaction 
mixture. Thermocycling was performed on an icycler thermal cycler (Bio-Rad, 
Hemel Hempstead, UK) over 40 cycles with 52.6ºC annealing temperature. 
PCR success was clarified through silver stain visualisation on 6% polyacryla-
mide gel electrophoresis. PCR products were purified using PCR purification 
kit (Qiagen) under manufacturer’s instructions. Sequencing was performed 
at Genome Enterprise Limited (Norwich, UK) and analyzed using Mutation 
Surveyor version 3.0 (Softgenetics, State College, PA). Mutations were con-
firmed through repeated PCR and sequencing.
Construction of mutation spectra. Mutation spectra were constructed 
using iMARS software (Morgan and Lewis, 2006).
Quantitative real-time MGMT gene expression analysis. Real-time PCR 
quantitation of MGMT transcripts was performed using TaqMan probes as 
detailed in the study by Zaïr et al. (2011).
Statistical analysis. Error bars on figures are SD around the mean. Dose-
response modeling was performed according to Gocke and Wall (2009), 
Johnson et al. (2009), and Gollapudi et al. (2013). Statistical analysis was per-
formed using SPSS version 20. Pairwise comparisons of each mutation spec-
trum were made using χ2 tests and the Adams-Skopek test (Adams and Skopek, 
1987) through HYPERG software (Cariello et al., 1994). Principle component 
analysis (PCA) of mutation spectra was performed using R version 9.2. Coding 
available on request. Real-time data analysis as per Doak et al. (2008).
REsULTs
A dose-response for MNU mutagenicity was obtained using 
the HPRT assay in AHH-1 cells. MNU was tested at 10-fold 
lower concentrations than previously tested by Doak et  al. 
(2007). Resulting HPRT mutants were sequenced and mutation 
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spectra constructed at critical doses of the dose-response to 
comment upon mutagenic mechanisms at different MNU con-
centrations. The hypothesized role of MGMT in DNA tolerance 
to low doses was tested by use of O6-benzylguanine–induced 
MGMT inactivation and the HPRT assay repeated.
Mutagenic Dose-Response for MNU 
in Lymphoblastoid Cells
The frequencies of HPRT mutants and relative plating effi-
ciency (RPE) were plotted against increasing concentrations of 
MNU (Fig. 1).
The dose-response for HPRT mutants in this study resembled 
that of a nonmonotonic curve (Fig. 1), where the lowest doses 
have the opposite effect to higher doses (Davis and Svendsgaard, 
1990). Dunnett’s post hoc analysis was performed on the 
raw data to compare all treatment MFs with control (DMSO 
and untreated). It was found that the NOGEL was 0.0075 µg/
ml (72.8nM, p  =  0.99), and the lowest observed genotoxic 
effect level (LOGEL) was 0.01 µg/ml (97nM, p  =  0.001) for 
point mutation induction. Furthermore, two-sided Dunnett’s 
analysis revealed that the MF at 0.0025 and 0.005 µg/ml was 
significantly lower than the control level (p < 0.05), following 
square root transformation based on Bartlett’s test for 
heterogeneity of variance (p > 0.05), and Kolmogorov-Smirnov 
normality test (p > 0.05). Curve estimations upon doses up to 
the NOGEL (0–0.0075 µg/ml) revealed that the dose-response 
fitted a quadratic model (p = 0.01) with a negative relationship 
substantiating the reduction in MF and appearance of a J-shaped 
dose-response. The gradient of the slope was −0.00075 (to 5d.p) 
with 95% confidence limits of −0.00133 to −0.00017. Therefore, 
we can conclude that the response did not fit a hockey stick nor 
a linear model, and there was a definitive reduction in MF, over 
several doses, compared with the negative control. Additionally, 
there were significantly fewer HPRT mutant colonies (data not 
shown) at 0.0025 µg/ml than at the control (p = 0.01), which 
ruled out potential influences of increased PE on MF calculation.
Sequence Analysis Revealed Significant Differences in 
Mutation Induction Over the Nonlinear Dose-Response
Sequence analysis was performed on 40 HPRT mutant colonies 
for each treatment. These were solvent (DMSO) control (0 µg/
ml MNU) and 0.00075 µg/ml and 0.025 µg/ml MNU represent-
ing below NOGEL and above LOGEL doses, respectively. The 
spectrum of mutations at the HPRT locus following treatment 
with increasing doses is shown in Figure 2. As expected, the vast 
majority of mutations occurred in the protein-coding region of 
the mRNA from position 167 to 824 bp. The mutation spectrum at 
0.00075 µg/ml MNU was different to that of the solvent control. 
FIG. 1. Nonlinear dose-response of MNU in AHH-1 cells quantified through the HPRT assay (solid line). RPE was used to assess toxicity (dotted line). 
*p < 0.05 using two-sided Dunnett’s test with square root transformed data based on Bartlett’s test for heterogeneity of variance (p > 0.05) and Kolmogorov-
Smirnov test for normality (p > 0.05).
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Eighteen of the forty mutants of the solvent control and 4 of the 
40 mutants following treatment with 0.025  µg/ml MNU con-
tained a possible duplication of 33 nt at 490–533 bp. These were 
excluded from statistical analysis to focus on point mutations, 
the major mutagenic mechanism of MNU. This was not found 
in mutants following treatment with 0.00075 µg/ml MNU. A GC 
→ TA transversion at 747 was also specific to MNU treatment, 
regardless of concentration. Many of the GC → AT transitions 
were only present following treatment with 0.025 µg/ml MNU. 
Each spectrum was significantly different (p = 0.000), adjudged 
by the Adams-Skopek test. Additionally, a χ2 test was performed 
on raw data, and each spectrum was significantly different: 0 ver-
sus 0.00075 (p = 2.3 × 10−61), 0 versus 0.025 (p = 4.7 × 10−65), and 
0.00075 versus 0.025 (p = 1.0 × 10−154). MNU-specific hot spots 
were defined as mutations occurring at > 5% of the total muta-
tions for each spectrum. At 0.00075 µg/ml, one hot spot (shown 
in Table 1) occurred at 747; 5′TGA → TCA. This was also found 
at 0.025 µg/ml with additional hot spots at 551; 5′AGA → AAA, 
555; 5′TGT → TAT and 556; 5′GTC → GAC. The vast majority 
of GC → AT mutations (76%) observed at 0.025 µg/ml MNU 
occurred at guanines preceded by a purine (5′Pu-G-N), which 
was to be expected (Zhang and Jenssen, 1991). PCA on mutation 
spectra further substantiated differences in mutation induction 
at increasing concentrations of MNU. The data were explained 
by two components, PCA1 (correlation factor = 0.9) and PCA2 
(correlation factor  =  0.1). PCA1 distinguished MNU treated 
from control spectra, and the second component separated the 
two MNU treatment groups. Most notably, of the mutations 
unique to 0.025 µg/ml, the vast majority were GC → AT transi-
tions, which accounted for the differences between treatments.
FIG. 2. Frequency of all base substitutions found along the nontranscribed strand of HPRT sequence at increasing concentrations of MNU.
TAbLE 1
Proportions of substitutions at the HPRT Locus Observed 
at Increasing Concentrations of MNU
*
* *
Substitution type
Percentage of total mutations (%)
0 µg/ml MNU
0.00075 µg/ml 
MNU
0.025 µg/ml 
MNU
GC → AT 15.0 12.5 45.9
AT → CG 29.0  7.8  5.1
AT → GC  9.3  7.8  8.9
GC → TA  9.3  7.8  3.0
AT → TA 22.4 14.1 16.2
CG → GC 15.0 50.0 20.7
Total number of 
mutations found
112 64 135
Notes. The values in bold represent the most predominant substitution at 
each concentration. n = 22 for 0 µg/ml, n = 40 for 0.00075 µg/ml, and n = 36 
for 0.025 µg/ml (see text for details).
*p ≤ 1 × 10˗60.
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Proportions of GC → AT Transitions Are Elevated at Doses 
Above the LOGEL
In the solvent control, a total of 112 base substitutions were 
found in 40 mutants. The most prominent spontaneous substi-
tutions were AT → CG transversions, constituting 29.0% of 
the spontaneous mutation spectra. Following treatment with 
0.00075 µg/ml, CG → GC transversions were most abundant, 
constituting 32 of 64 (50%) substitutions observed. The spec-
trum changed upon treatment with 0.025 µg/ml MNU, where 
GC → AT transitions were the predominant alterations, as 
expected from MNU exposure, forming 45.9% of the mutation 
spectrum. Of all the mutations, the increase in GC → AT tran-
sitions most closely reflected the increase in MF (Fig. 3). The 
change in proportion of GC → AT transitions was accompanied 
by a change in the number of mutants found to harbor a GC → 
AT transition, from 52.5% (21/40) mutants in the control spec-
trum to 17.5% (7/40) mutants at 0.00075 µg/ml to 72.5% (29/40) 
mutants at 0.025 µg/ml. Therefore, results were not biased by a 
single mutant containing many GC → AT transitions.
MGMT Inactivation Changes the Shape  
of the Dose-Response
O6-benzylguanine (O6BG) was used to specifically inhibit 
MGMT activity in AHH-1 cells. A  dose-response for MNU 
mutagenesis was obtained in MGMT-inactivated AHH-1 cells 
(Fig. 4B). There was a drastic change in the shape of the dose-
response (Fig. 4). There was a 10-fold reduction in the LOGEL 
from 0.01 µg/ml MNU (p = 0.015) in MGMT-active cells to 
0.001  µg/ml (p  =  0.04) in MGMT-inactivated cells. Solvent 
control MF values between MGMT-active and -inactive cells 
were not significantly different, and so a valid comparison 
between the two experiments can be made (lowest p = 0.475 
using a one-way ANOVA).
The quadratic model better fitted the data (p  =  0.01) in 
AHH-1 cells without MGMT inactivation (Fig. 4A). In con-
trast, following MGMT inactivation, the linear model better 
explains the data (p = 0.04) (Fig. 4B). Short-term cytotoxic-
ity/cytostasis studies showed that MNU treatment following 
MGMT inactivation was not toxic at the doses used (data not 
shown). In addition, 0.0075 µg/ml MNU (NOGEL in MGMT-
active AHH-1 cells) caused a 3.5-fold higher MF. This was 
accompanied by a 68.5% increase in GC → AT transitions 
and a 66% increase in the number of mutants harboring a GC 
→ AT transition.
Increase in MF in MGMT-Inactive Cells Occurs Only 
Below the LOGEL
The MF ratio between AHH-1 cells differing in MGMT 
proficiency was calculated by dividing the MF in presence 
of O6BG (MGMT inactive) by the MF in absence of O6BG 
(MGMT active) at each dose (Fig. 5).
The MF in MGMT-inactivated cells was, at most, fivefold 
higher than in MGMT-active cells. However, the difference 
in MNU potency, as a function of MGMT activity, was only 
observed at doses below the LOGEL (0.01  µg/ml MNU in 
MGMT-active AHH-1 cells). There was very little difference 
FIG. 3. The proportion of GC → AT changes (bars) increases in concordance with the increase in HPRT MF (line) observed in Figure 1.
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FIG.  4. Linear regression outputs comparing linear to quadratic dose-
responses for MNU-induced mutant frequencies in MGMT-active (A) and 
MGMT-inactive AHH-1 cells (B) at the NOGEL (0.0075 µg/ml) and below. 
The MGMT-active dose-response was quadratic below the NOGEL (p < 0.05) 
and displayed a negative gradient for the linear regression (p  <  0.05) at 
−0.0007 ± 0.0006 (A). The MGMT-inactive dose-response was linear (p = 0.15) 
and had a clearly positive gradient (p < 0.05) (B). Linear model (solid line), 
observed data (open circles), and quadratic model (dashed line).
FIG. 5. The fold change in MF in MGMT-active and -inactive AHH-1 cells plotted on a log-linear axis.
in MF at the LOGEL and higher doses of MNU. Additionally, 
because the MF of solvent controls did not differ significantly 
to the untreated control, the MF in presence and absence of 
O6BG was compared at each dose using a two-tailed t-test. 
Significance was only seen at doses below the LOGEL.
Validation of O6BG-Mediated MGMT Inactivation
Attempts to validate the reduction in MGMT activity 
in AHH-1 cells following O6BG treatment were made but 
were unsuccessful. AHH-1 cells have comparatively lower 
MGMT levels than other cell lines available in our laboratory 
(Supplementary fig. 1). In AHH-1 cells, MGMT transcripts can 
be detected at a very low level, and so it seems likely that the 
protein is beneath the level of detection of activity and protein 
assays. The limit of detection of the assay is 0.63 fmol/mg pro-
tein (Bobola et al., 2007; Kaina et al., 1991). It is possible that 
MGMT exists at a level below 0.63 fmol/mg protein in AHH-1 
cells, and lack of assay sensitivity prevents detection. However, 
the cellular presence and effect of O6BG were made clear by 
the potentiation of high-dose MNU toxicity over 48 h. The 
toxic dose 50 (TD
50
) of MNU in MGMT-active AHH-1 cells, as 
measured by RPD, was 2 µg/ml, following O6BG administra-
tion; the RPD was reduced twofold.
DIsCUssION
The aim of this study was to establish the biological relevance 
of low doses of MNU to substantiate the growing acceptance 
of “low-dose tolerance” to monofunctional alkylating agents.
A NOGEL for MNU mutagenesis was identified at 0.0075 µg/
ml (72.8nM) MNU and a LOGEL of 0.01  µg/ml (97nM) in 
AHH-1 cells. This is in support of recent evidence that pertains 
tolerance to low-dose MNU in a number of in vitro and in vivo 
models (Bryce et al., 2010; Lynch et al., 2011; Pottenger et al., 
2009). The alkyl nitrosoureas, in which MNU is classified, are 
more mutagenic than alkyl alkanesulfonates due to the higher 
proportion of mutagenic adducts induced. Suter et  al. (1980) 
found that MNU was 20-fold more mutagenic than MMS in 
V79 cells. Therefore, one would expect a MNU LOGEL to 
exist at a 20-fold lower concentration than a LOGEL for MMS. 
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Pottenger et al. (2009) found the LOGEL of MNU to be only 
2.5-fold lower than the LOGEL for MMS in L1578Y mouse 
lymphoma cells. In our study, the LOGEL for MNU is 117-
fold lower than that of MMS (1.25 µg/ml, 11.35µM) identified 
in the same experimental system (Doak et  al., 2007). These 
drastic differences in mutagenic potency between cell types and 
alkylating agents can be explained by increased sensitivity to 
O6MeG in AHH-1 cells compared with V79 and L1578Y rodent 
cells, potentially reflecting differential DNA repair capacities or 
could be an artifact of the differences in MNU purity between 
the studies.
This study is the first to report an apparent reduction in MF 
at 0.0025 and 0.005 µg/ml MNU compared with the solvent 
control, which is suggestive of a nonmonotonic dose-response. 
The reduction cannot be attributed to toxicity, cytostasis, or an 
artifact of the calculation. Therefore, it is possible that there is 
a biological mechanism responsible for the reduction in MF. 
Conolly and Lutz (2004) postulate a number of prerequisites 
that would allow a theoretical mechanism to account for the 
reduction in MF. Assuming these are satisfied, we hypothesize 
that 0.0025 µg/ml and 0.005 µg/ml caused modification of DNA 
repair capacities or detoxification mechanisms that removed or 
prevented damage from MNU and from endogenously gener-
ated genotoxins (e.g., from mitochondrial processes). Potential 
upregulation of DNA repair has not been fully investigated in 
this study. However, due to the well-defined protective role 
of MGMT against MNU mutagenesis, we quantified MGMT 
mRNA through quantitative real-time PCR. MGMT expression 
was unmodified in response to MNU exposure (Supplementary 
fig.  1). This was unexpected given the increase in MGMT 
expression 4 h following MMS exposure (Doak et al., 2008). 
However, we cannot rule out the possibility of a posttransla-
tional modification that may lead to upregulation of MGMT 
molecules in human cells.
This is a novel study to report on the mechanism of MNU 
mutagenesis at low doses, particularly below the NOGEL. The 
changes in DNA sequence at the HPRT locus was compared 
between the negative control and treatment groups. Each of the 
possible base substitutions was observed. For the majority of 
substitutions observed, the mutagenic mechanism responsible 
is unknown, potentially involving well-characterized changes 
in base chemistry, errors in replication, and possibly other 
adducts of the MNU spectra. Of interest to the study are the 
differences between the spectra. In particular, the differences 
between solvent control and 0.00075  µg/ml MNU (below 
NOGEL) highlight the cellular presence and effect of MNU 
at a dose below the NOGEL (0.00075 µg/ml). Crucially, this 
evidence indicates a postadduct cytoprotective mechanism, 
i.e., DNA repair to account for the lack of increase in MF. Of 
interest is the absence of sequence alteration in the region 490–
523 bp following treatment with 0.00075 µg/ml MNU, which is 
present in the solvent control and at higher MNU doses. This 
substantiates the argument of a nonmonotonic dose-response 
if low dose of MNU upregulates cytoprotection, which would 
prevent endogenous damage from causing mutations. However, 
this study cannot confirm this. The question whether MNU is 
a hazard because of the change in mutagenic profile below the 
statistical NOGEL still exists (Professor Bhaskar Gollapudi, 
personal communication).
Although this is the first study to show a mutation spectra 
dose-response for direct-acting genotoxins, it has previously 
been reported for phenobarbitol, a nongenotoxic carcinogen 
(Shane et al., 2000). Changes in the mutation spectrum at a 
nontumorigenic dose of phenobarbitol were attributed to oxi-
dative stress through the induction of cytochrome P450 fol-
lowing exposure. Below the NOGEL, GC → TA transversions 
predominate (Table 1) and are noted in previous studies albeit 
to a lesser extent (Van Zeeland et al., 2008), possibly owing 
to dilution by more prominent mutations following treatment 
with higher doses. The adduct responsible is not known at 
present, suffice to say that if O6MeG adducts are tolerable 
through repair, then other adducts are dominant at low doses. 
The statistically significant increase in MF at 0.025 µg/ml was 
accompanied by a drastic increase in the proportion of GC → 
AT transitions, which accounted for the differences between 
the treated spectra following PCA. O6MeG has a well-defined 
fixation mechanism into GC → AT transitions (Beranek et al., 
1983; Loveless, 1969). We have previously shown that this 
adduct and mutation are produced at high levels following 
treatment with MNU (Jenkins et  al., 2005). Another mis-
coding lesion, O4-methylthymine (O4MeT), is repaired less 
efficiently than O6MeG but is formed at much smaller quanti-
ties, i.e., 0.1–0.7% of total alkylation events (Beranek, 1990). 
O4MeT miscodes during replication causing TA → CG transi-
tions (Klein et al., 1994). Palombo et al. (1992) found 20 GC 
→ AT transitions and 1 TA → CG transitions at the human 
gpt gene following MNU exposure, attributable to O6MeG 
and O4MeT. O6MeG causes the majority of MNU-induced 
point mutations (Sledziewska-Gójska and Torzewska, 1997). 
Therefore, it is reasonable to conclude that the observed dose-
response and NOGEL are dependent upon the biological 
effect of O6MeG.
Inactivation of MGMT by O6BG administration (a well-
documented and specific method of MGMT “knockout” (Pegg 
et al., 1993; Ueno et al., 2006)) sensitizes cells to the adverse 
effects of O6-guanine methylation (Dolan et  al., 1991; Fritz 
and Kaina, 1992; Kaina et  al., 1991; Tsuzuki et  al., 1996). 
Validation of inactivation is difficult in AHH-1 cells because it 
is likely that MGMT exits at a level, which is below detection. 
In our study, such sensitization is evidenced by the following:
•	 10-fold decrease in LOGEL in MGMT-inactive cells
•	 Significant change in the dose-response following MGMT 
inactivation (Fig. 4).
These effects cannot be attributed to O6BG itself because 
it was not mutagenic nor did it cause increased toxicity or 
cytostasis following administration, consistent with published 
literature (Wedge and Newlands, 1996). Additionally, O6BG 
has no known pleiotropic effects within cells but has a well-
defined reaction mechanism with MGMT (Kaina et al., 2010; 
Pegg et  al., 1993; Ueno et  al., 2006; Xu-Welliver and Pegg, 
2002). Therefore, MNU potentiation can only be attributable 
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to the specific O6BG-mediated inactivation of MGMT, and the 
resultant increased persistence and subsequent replication of 
O6MeG following MNU treatment. A caveat is the interreplicate 
variation made visible in Figure  4B. This may reflect the 
heterogeneity in efficiency of inhibition by O6BG across a 
cell population. MGMT inactivation resulted in a change 
in the dose-response from a NMDR, U-shaped pattern to a 
linear relationship at the doses tested. This strongly implicates 
MGMT in the nonlinear mutation induction curve for MNU. At 
higher MNU concentrations (exceeding 0.01 µg/ml MNU, i.e., 
LOGEL), O6BG did not potentiate MNU mutagenicity. This 
has been observed in MGMT-deficient cells, e.g., HeLa MR 
(Chen et al., 1993). It is possible that supra-LOGEL doses of 
MNU cause MGMT loss through increased demand for repair 
of O6MeG. This would explain the lack of effect of O6BG at 
higher doses (Fig.  5). This provides evidence to suggest that 
the NOGEL is dependent upon cellular MGMT levels. The 
increase in MF and GC → AT transitions is attributable to the 
loss of MGMT at doses > NOGEL.
CONCLUsIONs
With recent evidence of low-dose nonlinear genotoxicity by 
alkylating agents, there is considerable impetus to determine 
the mechanism of low-dose mutation induction. We have iden-
tified a NOGEL for point mutation induction in AHH-1 cells 
treated with MNU that is dependent upon postadduct DNA 
repair. We report the involvement of MGMT in the repair of 
O6MeG adducts at the NOGEL and below.
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